Affiliation:
1. Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China
2. Department of Gerontology, Jiangxi University of Traditional Chinese Medicine Affiliated Hospital, Nanchang, Jiangxi Province, China
Abstract
Introduction:
Fufang Banmao capsule (FFBM), a traditional Chinese medicine, has been used to
treat primary liver cancer (PLC) for several years. However, the bioactive ingredients, and mechanism of
FFBM for treating PLC remains unclear. Our objective is to utilize network pharmacology to investigate these
aspects and subsequently validate their effectiveness through clinical data.
Materials and Methods:
The FFBM ingredients were obtained from the HERB database and screened for
bioactive ingredients using the SwissTargetPrediction database. The PharmMapper and GEO database were
used to acquire targets and differentially expressed genes (DEGs) for FFBM and PLC, respectively. Common
targets were identified using Venn diagrams, followed by enrichment and protein-protein interaction (PPI)
analysis. Furthermore, the Cytoscape software was utilized to identify Hub genes and construct the ingredienttarget-
pathway network. Subsequently, patients diagnosed with unresectable PLC who underwent transcatheter
arterial chemoembolization (TACE) at our hospital between January 2008 and December 2019 were retrospectively
collected. Finally, Cox analysis was conducted to reveal the role of FFBM in the treatment of unresectable
PLC.
Results:
FFBM had 232 targets, and PLC had 1582 DEGs. HSP90AA1 and SRC were identified as crucial targets.
Alpha-santalol, glycyrrhizin, and morroniside were identified as the top three bioactive ingredients. Enrichment
analysis revealed a significant connection between FFBM utilization for treating PLC and multiple
pathways, such as chemical carcinogenesis, PI3K-AKT, Rap1, FoxO, MAPK, and VEGF pathway. Clinic data
revealed that consuming FFBM significantly improved the prognosis of unresectable PLC with a hazard ratio
of 0.69.
Conclusion:
Our study identified the bioactive ingredients of FFBM and its potential mechanisms for treating
PLC. Additionally, we validated the effectiveness through clinical data.
Publisher
Bentham Science Publishers Ltd.